DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Press Release.
Intercept receives complete response letter from FDA for obeticholic acid for the treatment of fibrosis due to NASH. Accessed on July 14, 2021 at:
https://ir.interceptpharma.com/news-releases/news-release-details/intercept-receives-complete-response-letter-fda-obeticholic-acid
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.